MedTrace Logo

Multiparametric MRI for Assessing Breast Cancer Response to Anti-HER2 Therapy

NCT03738553 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 13

Last updated 2026-05-04

No results posted yet for this study

Summary

This is a single institution, observational research study in which patients are observed using DWI/DCE MRI imaging before and after receiving neoadjuvant anti-HER2 therapy.

Conditions

Interventions

DEVICE

MRI

Diffusion Weighted Imaging and Dynamic Contrast enhanced MRI

DRUG

Trastuzumab

Single dose of Trastuzumab prior to surgery

Sponsors & Collaborators

Principal Investigators

  • Savannah Partridge · Fred Hutch/University of Washington Cancer Consortium

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-08-31
Primary Completion
2020-09-30
Completion
2026-03-01
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03738553 on ClinicalTrials.gov